Fam3c

Fam3c is a cardioprotective therapeutic candidate being developed by Forcefield Therapeutics for the treatment of acute myocardial infarction and the prevention of heart failure. Identified through the FunSel protein screening technology in collaboration with King's College London, Fam3c is one of several secreted proteins shown to preserve cardiac function and prevent tissue damage in preclinical models. The therapeutic is designed for administration immediately following a heart attack to protect cardiomyocytes. Its multi-modal mechanism of action includes the activation of autophagy (cellular repair), the reduction of apoptosis (programmed cell death), and anti-fibrotic activity achieved through the suppression of TGF-beta signaling. While the primary development focus is a recombinant protein therapeutic, Forcefield is also exploring an AAV-based gene therapy delivery method in partnership with Freeline Therapeutics.

Other names

Fam3c protein therapeuticFam-3c protein therapeuticFam 3c protein therapeuticFam3c gene therapyFam-3c gene therapyFam 3c gene therapy